Loading…
Biotech Next Gen 2021 has ended
avatar for Kristen Hege, M.D.

Kristen Hege, M.D.

Bristol Myers Squibb
SVP, Early Clinical Development, Oncology/Hematology and Cell Therapy
Dr. Hege is SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb (BMS) where she is responsible for advancing a pipeline of small molecules, biologics and cell therapies from first-in-human studies through clinical proof-of-concept. In additon, she led the bluebird-partnered BCMA CART cell program (ide-cel; Abecma) in multiple myeloma from inception through FDA approval. Prior to joining BMS she was head of Translational Development at Celgene and has also held multiple executive roles at Cell Genesys, Cellerant, and Theraclone.
In addition to her work at BMS, Dr. Hege is a Clinical Professor of Medicine at UCSF where she continues to see patients with blood cancers weekly.  She also serves on the Board of Directors of Mersana Therapeutics and Graphite Bio and was elected to the Board of Directors for the Society for Immunotherapy of Cancer (SITC) for a 3-year term from 2016-2019.
Dr. Hege received her M.D. at UCSF and residency and hematology/oncology subspecialty training at Harvard and UCSF, respectively. In 2015, she was recognized by Fierce Biotech as one of the top 12 women in Biopharma. Her career path and long history with CAR T cell development was featured as part of the 25th anniversary celebration of Nature Medicine.

My Speakers Sessions

Tuesday, June 22
 

1:00pm EDT